SYNCORE BIOTECHNOLOGY CO.,LTD SynCore Biotechnology Co.,Ltd Share Price
Equities
4192
TW0004192000
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.1 TWD | -2.28% |
|
+3.74% | +22.66% |
| Sales 2022 | 15.86M 486K 40.62M | Sales 2023 | 20.2M 620K 51.74M | Capitalization | 1.35B 41.42M 3.46B |
|---|---|---|---|---|---|
| Net income 2022 | -189M -5.8M -484M | Net income 2023 | -38M -1.17M -97.34M | EV / Sales 2022 | 171 x |
| Net cash position 2022 | 205M 6.28M 524M | Net cash position 2023 | 269M 8.26M 690M | EV / Sales 2023 | 53.5 x |
| P/E ratio 2022 |
-15.5
x | P/E ratio 2023 |
-32.2
x | Employees | 40 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.28% | ||
| 1 week | +3.74% | ||
| Current month | +22.66% | ||
| 1 month | +22.66% | ||
| 3 months | +28.51% | ||
| 6 months | +12.14% | ||
| Current year | +22.66% |
1 week
45.90
52.50
1 month
38.0057.80
Current year
34.5557.80
1 year
34.5574.67
3 years
34.55550.22
5 years
34.55580.17
10 years
34.55580.17
| Managers | Title | Age | Since |
|---|---|---|---|
Mu Huan Su
CEO | Chief Executive Officer | - | 09/08/09 |
Chia Hao Liang
DFI | Director of Finance/CFO | - | 01/13/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Feng Chen
BRD | Director/Board Member | - | 27/13/27 |
Chih Wen Li
FOU | Founder | - | 26/08/26 |
Mu Huan Su
CEO | Chief Executive Officer | - | 09/08/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 47.1 | -2.28% | 55,004 |
| 29/24/29 | 48.2 | -8.19% | 192,616 |
| 26/24/26 | 52.5 | +9.83% | 270,912 |
| 25/24/25 | 47.8 | -.--% | 14,544 |
| 24/24/24 | 47.8 | +5.05% | 29,468 |
End-of-day quote Taipei Exchange, April 30, 2024
More quotes
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.
| 1st Jan change | Capi. | |
|---|---|---|
| +22.66% | 50.79M | |
| -3.16% | 102B | |
| +1.62% | 96.09B | |
| +2.13% | 22.28B | |
| -17.02% | 21.4B | |
| -8.72% | 18.14B | |
| -39.98% | 17.02B | |
| -14.20% | 16.09B | |
| +7.62% | 13.83B | |
| +33.24% | 11.97B |
- Stock Market
- Equities
- 4192 Stock
